

APPROVED – CSU IBC Meeting Minutes

Meeting title	CSU IBC Meeting September 2025
Date	September 10, 2025
Convened at	12:02PM MST
Location	Microsoft Teams (Virtual Meeting)
Open or closed meeting (If closed, why?)	The meeting open.
Review of prior meeting minutes	August 13, 2025 minutes were not ready to be reviewed.
Adjournment	12:39 PM MST
Recorded by	M. Ramey & C. Johnson

Attendees

Check if Attending (Members):	Check if Attending (Alternate Members):
<input type="checkbox"/> Jessica Ayers, Animal expert	<input type="checkbox"/> Lon Kendall, Director LAR
<input type="checkbox"/> Donald Bade, Unaffiliated	
<input checked="" type="checkbox"/> Angela Bosco-Lauth, Veterinary Virology	
<input checked="" type="checkbox"/> Chaoping Chen, Chair	
<input checked="" type="checkbox"/> Jason Cummings, lab representative	
<input checked="" type="checkbox"/> Dan Frazen, Unaffiliated	
<input checked="" type="checkbox"/> Jean Peccoud, Synthetic Biology	
<input checked="" type="checkbox"/> Brendan Podell, Mycobacteria specialist	
<input checked="" type="checkbox"/> Ann Powers, Virology	
<input checked="" type="checkbox"/> Robyn Roberts, Plant expert	
<input checked="" type="checkbox"/> Joanie Ryan, Assistant Biosafety Director	<input checked="" type="checkbox"/> Rebecca Moritz, Biosafety Office Director*
<input type="checkbox"/> Tony Schountz, Virology	<input checked="" type="checkbox"/> Christine Johnson, IBC/IRE Manager, Alternate-at-Large*
Quorum = 7 voting members; 9 in attendance	*non-voting at this meeting
Non-Voting Members:	
<input type="checkbox"/> James Graham, EHS Director	
<input type="checkbox"/> Joni Van Sickle, Occupational Health Coord.	
ORCC Staff (non-voting):	
<input checked="" type="checkbox"/> Michelle Ramey, Assistant Compliance Coord.	<input checked="" type="checkbox"/> Sonia Aleman Rivera, Assistant Biosafety Officer
<input type="checkbox"/> Nicole Marlenee, Biosecurity Specialist	<input checked="" type="checkbox"/> Kelly Kim, Assistant Biosafety Officer
<input checked="" type="checkbox"/> Scott Van Scotter, Biosafety Trainer	
Additional Guests:	
None	

Quorum was maintained throughout. Any member with a conflict of interest left the meeting during discussion and/or committee determination on the conflicted items.

1. Agent/Project Review

a. PI name/Lab	VandeWoude Lab
Project Number and Title	23-053B: Emerging infectious disease research of zoonotic potential, genomic surveillance of avian influenza viruses in select mammalian species
Agents used	<ul style="list-style-type: none"> • <i>Avian Influenza, Influenza A</i> – Strain: any/unknown
Project Overview	This project aims to develop assays to assess seroantibodies to avian influenza from a variety of species. The Lab will test serum from biobanked samples, and from serum collected opportunistically at the veterinary diagnostic lab. All serum will be heat inactivated prior to use.
Planned Modifications	N/A
NIH Guidelines Section	N/A
Proposed containment conditions (BSL, ABSL, etc.)	BSL2
Discussion	<p>This is an experienced PI in MIP</p> <ol style="list-style-type: none"> 1. The IBC requests the temperature and time used for heat inactivation be added. 2. All personnel involved in the project need to complete the BSC training.
Verification of training	Some Lab members need to complete training.
Verification of facilities	The lab is up to date on lab inspections.
Motion	A motion was made to approve the project pending modifications described above (see Discussion).
Vote	The motion was unanimously approved.

b. PI name/Lab	Bowen Lab
Project Number and Title	25-057B: Immunization of chickens against avian influenza using a helper-independent adenovirus vector
Agents used	<ul style="list-style-type: none"> • <i>Influenza A virus</i> (highly pathogenic avian)– Strain: 2.3.4.4b isolate
Project Overview	This project will evaluate a replication-defective adenovirus expressing an HA protein as a vaccine in chickens against HPAIV
Planned Modifications	The vaccine is made in a made lab and provided by the sponsor; the recombinant vaccine will be tested in vivo.
NIH Guidelines Section	III-D-1/III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL3/ABSL3
Discussion	<p>This is an experienced PI in BMS</p> <ol style="list-style-type: none"> 1. The IBC requested that shower out procedures be added under variability of PPE since working with HPAIV.
Verification of training	All lab personnel training is current.
Verification of facilities	The lab is up to date on lab inspections.
Motion	A motion was made to approve the project pending modifications described above (see Discussion).

Vote	The motion was unanimously approved.
-------------	--------------------------------------

c. PI name/Lab	Foy Lab
Project Number and Title	25-058B: Immunization against arboviruses with recombinant probiotic bacteria
Agents used	<ul style="list-style-type: none"> • <i>West Nile virus</i> (WNV)- Strain: local Fort Collins strains • <i>St. Louis encephalitis virus</i>- Strain: regional strains from CA and AZ
Project Overview	This project aims to develop avian oral vaccines expressing West Nile and other arbovirus antigens. Birds will be immunized and evaluated to determine if they develop immune correlates of protection and if arbovirus titers are reduced following challenge.
Planned Modifications	The Lab is making recombinant vaccine constructs with a non-pathogenic probiotic that will express WNV and other arbovirus antigens. The recombinant vaccine will be tested in vivo.
NIH Guidelines Section	III-D-2/III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL2/ABSL2
Discussion	<p>This is an experienced PI in MIP</p> <ol style="list-style-type: none"> 1. The IBC requested more details regarding the in vitro work for this project 2. Provide more information regarding the types of birds used 3. Clarify which tasks are occurring at BSL-3 vs BSL-2 4. Specify in vivo PPE for ABSL-2 vs ABSL-3 5. Clarify the funding source
Verification of training	Some Lab members need to complete training.
Verification of facilities	The lab is up to date on lab inspections.
Motion	A motion was made to approve the project pending modifications described above (see Discussion).
Vote	The motion was unanimously approved.

d. PI name/Lab	McKay Lab
Project Number and Title	25-059B: Identification of Durable Disease Tolerance Gene(s) under Drought Stress in Maize
Agents used	<ul style="list-style-type: none"> • Bacteria - <i>Xanthomonas vasicola vasculorum</i>
Project Overview	The project aims to understand the effect of drought on disease tolerance in Maize. <i>Xanthomonas vasicola vasculorum</i> will be studied in the project under dry and wet condition.
Planned Modifications	NA
NIH Guidelines Section	NA
Proposed containment conditions (BSL, ABSL, etc.)	BSL1/BSL1-P
Discussion	<p>This is a new PI in AgBio</p> <p>There are missing details, making it difficult to appropriately review this Registration. There was a suggestion to Table the</p>

	decision and send the Bio Registration back to the PI to add more information.
Verification of training	All lab personnel training is current.
Verification of facilities	The Lab is new and needs to schedule a Biosafety Outreach Visit.
Motion	Motion was made to Table the review pending PI clarifications.
Vote	The motion to Table the review was unanimously approved.

e. PI name/Lab	Kading Lab
Project Number and Title	25-060B: Arbovirus surveillance of mosquitoes from Myanmar
Agents used	<ul style="list-style-type: none"> • <i>Japanese encephalitis virus</i> • <i>Zika Virus (ZIKV)</i>
Project Overview	This project is investigating the circulation of mosquito-borne viruses across a landscape gradient in Myanmar by collecting mosquitoes and evaluating mosquito species composition and arbovirus prevalence, habitat, potential virus isolations, and blood host identifications for engorged mosquitoes.
Planned Modifications	NA
NIH Guidelines Section	NA
Proposed containment conditions (BSL, ABSL, etc.)	BSL3
Discussion	<p>This is an experienced PI in MIP</p> <ol style="list-style-type: none"> 1. The IBC recommends the homogenization of mosquitoes be done at BSL3 and then degrading the samples to BSL2 when appropriate. 2. The IBC requests more details regarding the homogenization procedure and verification that no sharps will be used. 3. The BSL for Chikungunya virus needs to be corrected from BSL2 to BSL3. 4. If Chikungunya is identified (or any other the virus not currently approved for the Lab) a new Pathogen Registration Form will need to be submitted.
Verification of training	Some Lab members need to complete training.
Verification of facilities	The lab is up to date on lab inspections.
Motion	A motion was made to approve the project pending modifications described above (see Discussion).
Vote	The motion was unanimously approved.

2. Amendments requiring full IBC review

a. PI name/Lab	Tsunoda Lab
Project Number and Title	16-066B: Regulation of ion channels and synaptic activity
Agents used (toxin)	Tetrodotoxin
Project Overview	Electrophysiological studies to examine the regulation of synaptic activity. In the study of miniature post-synaptic currents, we block voltage-gated Na ⁺ channels with tetrodotoxin.

Amendment request	Amendment to add the animal model, <i>Drosophila melanogaster</i> , for this project
Planned Modifications	Transgenic <i>Drosophila</i> expressing GFP in targeted cells
NIH Guidelines Section	III-D-4
Proposed containment conditions (BSL, ABSL, etc.)	BSL1
Discussion	This is an experienced PI from BMS The IBC requests the statement regarding Goggles being available but only used when needed, be corrected to reflect the eye-protection policy which requires eye protection to be worn in the lab at all times.
Verification of training	All lab members are up to date on the required training.
Verification of facilities	The is up to date on lab inspections.
Motion	A motion was made to approve the amendment request pending modifications described above (see Discussion)
Vote	The motion was unanimously approved.

3. New Business – none

4. Unfinished Business - none

5. Reports

a. Coordinator’s Report	Next IBC meeting: Wednesday, October 8, 2025
b. Biosafety Office Report	1. Inspections update: The Biosafety Office is still waiting for CDC’s response to our response to their report 2. Incident Reports: There were no incidents involving recombinant material during the past quarter.

6. Items to be read into the minutes

a. Items Reviewed at Previous IBC Meeting and Approved After Modification were completed	<p>1. Bowen, Richard</p> <p>a. Project: <u>Efficacy of new Brucellosis vaccines in mice (25-047B)</u>; BSL3/ABSL in mice, rDNA. NIH Guidelines category non-exempt rDNA: III-D-4</p> <p>2. Mehaffy, Martha</p> <p>a. Agent: <i>Staphylococcus spp</i> – Stain: any; BSL2</p> <p>b. Agent: <i>Coliforms</i> – Strain: any; BSL2</p> <p>c. Project: <u>Whole genome sequencing of <i>Staphylococcus</i> and <i>Coliform</i> bacteria from the environment (25-048B)</u>; BSL2. NIH Guidelines category non-exempt rDNA: NA</p> <p>3. Schwerdtfeger Lab (new PI/new registration)</p> <p>a. Pathogen Registration Forms</p> <p>i. Bacteria - <i>Salmonella enterica</i></p>
---	--

	<ul style="list-style-type: none"> ii. Bacteria - <i>Pseudomonas Aeruginosa</i> iii. Virus - <i>Epstein-Barr Virus</i> (Human gammaherpesvirus-4) iv. Virus - <i>Human cytomegalovirus</i> (human herpesvirus-5) <p>b. Project: <u>Human tissue and biofluid markers of neurodegenerative disease</u> (25-0XXB); BSL2; human sample. NIH Guidelines category non-exempt rDNA: NA</p>
<p>4. Items Reviewed and Approved by the Biosafety Officer or Chair since the last meeting</p>	<p>None</p>